Zobrazeno 1 - 10
of 24
pro vyhledávání: '"MAKOTO NAGAMATA"'
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1668-1672 (2021)
Abstract Background Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation a
Externí odkaz:
https://doaj.org/article/91860ec955834aad8eff9c58cb249c2c
Autor:
Yoshiro Nakahara, Shinichiro Mikura, Makoto Nagamata, Tomoya Fukui, Jiichiro Sasaki, Noriyuki Masuda
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 2, Pp 428-432 (2017)
Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in non-small cell lung cancer. A 70-year-old male presented with a stage IV non-small cell lung cancer. The patient was treated with pemetrexed as third-line chemothera
Externí odkaz:
https://doaj.org/article/2f70609f23d14b308ad6860e19393bfe
Autor:
Yuki Misumi, Hiroaki Okamoto, Jiichiro Sasaki, Noriyuki Masuda, Mari Ishii, Tsuneo Shimokawa, Yukio Hosomi, Yusuke Okuma, Makoto Nagamata, Takashi Ogura, Terufumi Kato, Masafumi Sata, Sakiko Otani, Akira Takakura, Koichi Minato, Yosuke Miura, Takuma Yokoyama, Saori Takata, Katsuhiko Naoki, Koshiro Watanabe
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated. Methods Patients aged > 70 years with untreated, measurable, LD-SCLC, perfor
Externí odkaz:
https://doaj.org/article/dd4e840758a14748af1cdd0051e88e34
Background Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next-generation anthracyclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7d5cfc947399065c9e2226f0dff86db
https://doi.org/10.21203/rs.3.rs-42543/v1
https://doi.org/10.21203/rs.3.rs-42543/v1
Autor:
Yoshiro Nakahara, Kageaki Watanabe, Yusuke Takagi, Yusuke Okuma, Satoshi Takahashi, Tatsuru Okamura, Makiko Yomota, Yukio Hosomi, Makoto Nagamata, Kuniko Sunami, Tsuneo Shimokawa
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:559-564
A vitamin B12 supplement is required in pemetrexed single agent therapy. Intramuscular administration is the method of choice; however, oral administration is simpler and easier and may be sufficiently effective. We conducted a Phase II study to eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f0fdf9cbf1795da61de53a9f7e6266
https://doi.org/10.1007/s00280-015-2954-x
https://doi.org/10.1007/s00280-015-2954-x
Autor:
MAKOTO NAGAMATA1, YUSUKE OKUMA1 y-okuma@cick.jp, YUKO YAMADA2, YUKIO HOSOMI1, TSUNEKAZU HISHIMA2
Publikováno v:
Oncology Letters. 2014, Vol. 8 Issue 2, p513-516. 4p.
Publikováno v:
Journal of bronchologyinterventional pulmonology. 24(2)
Thymic carcinoma is a rare cancer, accounting for only 1% to 4% of thymic epithelial tumors. Endobronchial metastasis is a rare presentation of these tumors. A 64-year-old man presented with a cough. Lung cancer was suspected because a chest radiogra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562d5b8153d0e36d21f6ed72cc22d48c
https://pubmed.ncbi.nlm.nih.gov/28323731
https://pubmed.ncbi.nlm.nih.gov/28323731
Autor:
Makiko Yomota, Mari Iguchi, Yukio Hosomi, Yusuke Okuma, Masahiko Shibuya, Yoshiro Nakahara, Hiroaki Okamoto, Yusuke Takagi, Tatsuru Okamura, Kuniko Sunami, Makoto Nagamata, Tsuneo Shimokawa
Publikováno v:
The Oncologist. 19:1194-1199
Background. Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time is at least 7 days. On the basis of previous pharmacokinetic and clinical studies, we hypothesized that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::328f94238b763efb25c6a69dc5d73861
https://doi.org/10.1634/theoncologist.2014-0221
https://doi.org/10.1634/theoncologist.2014-0221
Publikováno v:
Oncology Letters
Thymic carcinoma is a rare cancer that is more aggressive and shows a poorer prognosis compared with thymoma. Molecular analysis has demonstrated that this entity is clearly distinct from thymoma. However, no definitive clinical management has been r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cebec9756b0f52ff57944a0485b97a7
http://europepmc.org/articles/PMC4081363
http://europepmc.org/articles/PMC4081363
Publikováno v:
Annals of Oncology. 27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e16ea2859e82e2929c5e41109c9d46
https://doi.org/10.1093/annonc/mdw599.014
https://doi.org/10.1093/annonc/mdw599.014